OncoMatch/Clinical Trials/NCT06988956
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
Is NCT06988956 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Nimotuzumab and Tegafur for esophageal squamous cell carcinoma.
Treatment: Nimotuzumab · Tegafur — investigators plan to conduct a multicenter, prospective, randomized controlled, open, phase clinical study to compare the efficacy and safety of nimotuzumab with concurrent chemoradiation alone in elderly participants with advanced esophageal squamous cell carcinoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Disease stage
Required: Stage II, III, IVA, IVB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: EGFR monoclonal antibody
Received EGFR mAb and EGFR-TKI within half a year
Cannot have received: EGFR tyrosine kinase inhibitor
Received EGFR mAb and EGFR-TKI within half a year
Lab requirements
Blood counts
HBG ≥90g/L; ANC ≥1.5×10^9/L; PLT ≥80×10^9/L
Kidney function
Plasma Cr ≤1.5 ULN or creatinine clearance (CCr) of 60 ml/min
Liver function
ALT and AST ≤2.5 ULN; ALT and AST 5 ULN; TBIL ≤1.5 ULN
Cardiac function
LVEF low normal value (50%)
Main organ function is normal, that is, meet the following criteria: Blood routine examination: HBG≥90g/L; ANC≥1.5×10^9/L; PLT ≥80×10^9/L; Biochemical examination: ALB≥30g/L; ALT and AST≤2.5ULN; ALT and AST 5 ULN; TBIL≤1.5ULN; Plasma Cr≤1.5ULN or creatinine clearance (CCr) of 60 ml/min; Echocardiographic assessment: left ventricular ejection fraction (LVEF) low normal value (50%)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify